Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.47 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6267681 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL16841696 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL8979913 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL19879529 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL25575155 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL19224560 | 1.00 | CA1 (0.55) | CA1CA2CA9CA12FFAR4 | |
| SCHEMBL5820623 | 0.86 | CA1 (0.43) | CA1CA2CA9CA12GBA1 | |
| SCHEMBL5820619 | 0.86 | CA1 (0.43) | CA1CA2CA9CA12GBA1 | |
| SCHEMBL23235646 | 0.86 | GRM2 (0.44) | CA1CA2CA9CA12GRM2 | |
| SCHEMBL13971270 | 0.85 | ALDH1A1 (0.46) | CA1CA2CA9CA12GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114437105-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| CN-1154650-C | Novel compounds | ������˹ҩƷ��˾ | 2004-06-23 | — | — | CN | disclosed |
| US-6251910-B1 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists | ASTRAZENECA UK LIMITED (GB) | 2001-06-26 | — | — | US | disclosed |
| CN-1270590-A | Novel compounds | ASTRA PHARMA PROD (GB) | 2000-10-18 | — | — | CN | disclosed |
| US-5506237-A | PROLYL-ENDOPEPTIDASE INHIBITOR; USEFUL FOR TREATING OR PREVENTING MEMORY LOSS DUE TO AGING, ANXIETY AND DEPRESSION | ADIR ET COMPAGNIE (FR) | 1996-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | CA1 2234/4885CA2 2516/4885CA9 1639/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | CA1 2234/4885CA2 2516/4885CA9 1639/4885 |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | CA1 2234/4885CA2 2516/4885CA9 1639/4885 |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | CA1 2234/4885CA2 2516/4885CA9 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.